Skip to main content


Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW: Prognostic factors after combined
modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007 Dec; 2(12):1117-23.
Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW: American
Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality
therapy for esophageal adenocarcinoma. American Joint Committee on Cancer. J Clin Oncol. 2007
Sep 20;25(27):4315-6.
Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, Iyer RB, Pan TS, Macapinlac
HA, Erasmus JJ.: PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007 NovDec;27(6):1635-52.

Bruzzi JF, Swisher SG, Truong MT, Munden RF, Hofstetter WL, Macapinlac HA, Correa AM, Mawlawi
O, Ajani JA, Komaki RR, Fukami N, Erasmus JJ.: Detection of interval distant metastases: clinical utility of
integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Division of Diagnostic
Imaging, M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. Cancer. 2007 Jan 1;109
Theisen J, Feith M, Stein HJ, Siewert JR.: Management of early esophageal cancer. Adv Surg.
Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, Kang S, Oh YT,
Chun M, Kim JH, Sheen SS, Lim HY: Low expression of Bax predicts poor prognosis in patients with locally
advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res. 2007 Jul 15;13
Mariette C, Piessen G, Triboulet JP.: Is there still a role for surgery in esophageal carcinoma in 2007?
Service de chirurgie digestive et générale, Hopital C. Huriez, place de Verdun. Bull Cancer. 2007 Jan 1;94
Mariette C, Piessen G, Triboulet JP.: Therapeutic strategies in oesophageal carcinoma: role of surgery
and other modalities. Lancet Oncol. 2007 Jun;8(6):545-53.
Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J.: Survival benefits from neoadjuvant
A nyelõcsõ 79
chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Australasian Gastro-Intestinal
Trials Group. Lancet Oncol. 2007 Mar;8(3):189-90.
Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky
BD, Roth JA, Willett CG.: Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment
trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
Radiation Therapy Oncology Group; USA Intergroup.
Lee DH, Kim HT, Han JY, Lee SY, Yoon SJ, Kim HY, Lee JS.: A phase II trial of modified weekly irinotecan
and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the
esophagus. 10.J Clin Oncol. 2007 Aug 20;25(24):3719-25. Links Cancer Chemother Pharmacol. 2008 Jan;61
Grünberger B, Raderer M, Schmidinger M, Hejna M.: Palliative chemotherapy for recurrent and metastatic
esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2705-14.
Kato H, Fukuchi M, Miyazaki T, Nakajima M, Tanaka N, Inose T, Kimura H, Faried A, Saito K, Sohda
M, Fukai Y, Masuda N, Manda R, Ojima H, Tsukada K, Oriuchi N, Endo K, Nonaka T, Shioya M, Ishikawa H,
Sakurai H, Nakano T, Kuwano H.: Prediction of response to definitive chemoradiotherapy in esophageal cancer
using positron emission tomography. Anticancer Res. 2007 Jul-Aug;27(4C):2627-33.
Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi
KD, Cho KJ, Kim JH.: Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission
tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative
chemoradiotherapy. Eur J Cancer. 2007 Jun;43(9):1385-91.
Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann
K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR.: PET to assess early metabolic
response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II
trial. Lancet Oncol. 2007 Sep;8(9):797-805.
Siewert JR, Lordick F, Ott K, Stein HJ, Weber WA, Becker K, Peschel C, Fink U, Schwaiger M.: Induction
chemotherapy in Barrett cancer: influence on surgical risk and outcome. Ann Surg. 2007 Oct;246(4):624-8.
Di Fiore F, Lecleire S, Pop D, Rigal O, Hamidou H, Paillot B, Ducrotté P, Lerebours E, Michel P.:
Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive
chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol. 2007 Nov;102(11):2557-63.
Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim
JS.: Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic
esophageal cancer. Med Oncol. 2007;24(1):33-7.
Raja SG, Salhiyyah K, Nagarajan K.: Does neoadjuvant chemotherapy improve survival in patients
with resectable thoracic oesophageal cancer? Interact Cardiovasc Thorac Surg. 2007 Oct;6(5):661-4.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao
Y, Voznyi E, Marabotti C, Van Cutsem E.: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared
with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma:
the V-325 Study Group. V-325 Study Group. J Clin Oncol. 2007 Aug 1;25(22):3205-9.
Kawabata R, Doki Y, Ishikawa O, Nakagawa H, Takachi K, Miyashiro I, Tsukamoto Y, Ohigashi H,
Sasaki Y, Murata K, Ishiguro S, Imaoka S.: Frequent brain metastasis after chemotherapy and surgery for
advanced esophageal cancers. Hepatogastroenterology. 2007 Jun;54(76):1043-8
Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H.: Targeting EGFR and HER-2
with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer.
2007 Aug 20;97(4):494-501.
Kanai M, Matsumoto S, Nishimura T, Shimada Y, Watanabe G, Kitano T, Misawa A, Ishiguro H,
Yoshikawa K, Yanagihara K, Teramukai S, Mitsumori M, Chiba T, Sakai Y, Fukushima M.: Retrospective analysis
80 Gastro Update 2008
of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for
advanced esophageal cancer. Int J Clin Oncol. 2007 Jun;12(3):224-7.
Samalin E, Ychou M.: Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms
from old concepts? Curr Opin Oncol. 2007 Jul;19(4):384-9.
Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, Ilson DH, Minsky BD, Rusch VW.: Pathogenesis,
diagnosis and therapeutic possibilities of esophageal cancer Siersema PD. Curr Opin Gastroenterol.
2007 Jul;23(4):456-61. 26. J Clin Oncol. 2007 Feb 10;25(5):507-12. Links. American Joint Committee on Cancer
staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal
adenocarcinoma. American Joint Committee on Cancer. J Clin Oncol. 2007 Sep 20;25(27):4315-6.
Rizk NP, Seshan VE, Bains MS, Ilson DH, Minsky BD, Tang L, Rusch VW.: Prognostic factors after combined
modality treatment of squamous cell carcinoma of the esophagus. J Thorac Oncol. 2007 Dec;2(12):1117-
2328. Drugs. 2007;67(17):2539-56.
Jackson C, Starling N, Chua YJ, Cunningham D.: Pharmacotherapy for oesophagogastric cancer.
Ku GY, Ilson DH.: Esophageal cancer: adjuvant therapy. Cancer J. 2007 May-Jun;13(3):162-7.
Gemici C.: The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy
improves tumor response in patients with esophageal adenocarcinoma. Cancer. 2007 Apr 1;109(7):1448-9;
author reply 1449.
Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, Walsh GL, Swisher SG, Vaporciyan
AA, Rice D, Welch A, Baker J, Faust J, Mansfield PF.: Impact of induction chemotherapy and preoperative
chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the
stomach or gastroesophageal junction. Ann Surg Oncol. 2007 Apr;14(4):1305-11.
Wng KL., Wu TT., Choi IS., Reseetkova E., Correa AM., Hofsteter Wl., Swisher SG., Ajani JA., Rashid A.,
Albarracin CT.: Expression of epidermal growth factor receptor in oesophageal and oesphagogastric junction
adenocarcinomas:association with poor outcome. Cancer 2007.Feb 15;109 (4),: 658-67.
Phase II study of docetaxol in combination with oxaliplatin in patients with metastatic or locally
advanced esophagogastric cancer previously untreated with chenmotherapy for advanced disease. Results of the
CECOG study ESGAS.1.2.001.
Hejna M., Zcherl J., Plushing U., Brodowitz T., Zielinski C., Raderer M.: ASCO 2007. Chicago, Abstr. 4527
Conroy T., Yataghene P., Etienne L., Michel P., Senellart J.,Raoul L., Mineur M., Mirabel A., Adenis.:
Definitiv chemo-radiotherapy (CRT) with folfox 4 or 5 FU-cisplatin as first line treatment for patients with
inoperable esophageal cancer : final results of randomized phase II. study. ASCO 2007 Chicago Abstr.4532.
Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ.: Salvage oesophagectomy after local failure of
definitive chemoradiotherapy. Br J Surg. 2007 Dec;94(12):1572;.
Salvage esophagectomy following definitive chemoradiotherapy.Nishimura M, Daiko H, Yoshida J, Nagai K
Gen Thorac Cardiovasc Surg. 2007 Nov;55(11):461-4; discussion 464-5.
Tanaka T, Fujita H, Sueyoshi S, Tanaka Y, Sasahara H, Mori N, Nagano T, Yamana H, Shirouzu K.: Secondline
combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer:
a preliminary report of initial experience. Chemotherapy. 2007;53(6):449-53. Epub 2007 Oct 22.
O’Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM.: Concurrent
oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma.
Cancer J. 2007 Mar-Apr;13(2):119-24.
Safran H., Dipetrillo T., Akerman P., Evans D., Steinhoff M., Benton D., PUriance J., Goldstein L., Kennedy
T.: Phase I/II. study of trastuzumab,paclitaxel, cisplatin and radiation for locally advanced, HER2 oveexpressing,
oesophageal adenocarcinoma. Int. J. Radiat Oncol.Biol. Phys. 2007 Feb.1;67 (2) 405-9.
A nyelõcsõ 81
Wei Q., Chen L., Sheng L., Nordgren H., Wester K., Carlsson J.: EGFR, HER2, HER3, expression inoesphageal
primary tumours, and corresponding metastases. Int. J.Oncol.2007 Sep;31(3) 493-9.
Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT.: A phase II trial of weekly
irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res. 2007 Jul-Aug;27(4C):2845-8.